Oncimmune inks collaboration with Genentech that broadens the "commercial footprint” of its ImmunoINSIGHTS service business

"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” said chief executive, Dr Adam Hill

Oncimmune -

Oncimmune Holdings PLC (AIM:ONC) said it has signed a collaboration to profile samples from Genentech's rheumatology clinical trials, broadening the "commercial footprint” of its ImmunoINSIGHTS service business.

Oncimmune’s NavigAID arrays will be used to characterise the auto-antibody profiles of patients taking part in studies for rheumatological diseases, including the autoimmune disease lupus.

Following the project’s completion, Genentech, which is now part of Swiss giant Roche, has the option to expand the contract to profile additional samples.

"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” Oncimmune chief executive, Dr Adam Hil said in a statement.

“This contract adds to the already substantial pipeline of contracted revenue through our ImmunoINSIGHTS business in the full-year 2021 and provides another opportunity to show how our NavigAID technology can assist partners in increasing their ability to better assess where their medicines could make an impact,” he added.

Quick facts: Oncimmune

Price: 174.5 GBX

Market: AIM
Market Cap: £110.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...


Market report: Negative FTSE as positive Covid cases rise amid further lockdowns

FTSE 100 opened in the red amid further lockdowns across Europe and fading hopes of a stimulus package before the US election. London’s main index slipped 29 points to 5,859 in early trading. UK inflation jumped to 0.5% in September from 0.2% in August. A rise in prices in cafes and...

12 hours, 41 minutes ago

2 min read